Inhalon Biopharma and Celltrion have initiated a Phase 1 study of IN-006 inhaled regdanvimab, Inhalon said. The study is funded in part by a US Army contract worth $7 million. In July 2021, Inhalon and Celltrion announced that they had partnered to develop the nebulized “muco-trapping” formulation of regdanvimab for the treatment of COVID-19. Celltrion’s intravenous formulation of regdanvimab has already received emergency use authorization for the treatment of COVID-19 in multiple countries.
Inhalon President and CEO John B. Whelan said, “COVID-19 infections in both vaccinated and unvaccinated people continue to rise and place an enormous burden on healthcare workers and hospitals. Inhalon’s muco-trapping antibody technology is the only therapeutic modality that can actively clear infectious virus from the lungs via natural mucus clearance, thereby eliminating the source of inflammation and viral spread. Combining Inhalon’s inhaled, muco-trapping platform with Celltrion’s highly effective anti-SARS-CoV2 antibody will likely create a new treatment that patients can self-administer to free up valuable healthcare resources.”
Read the Inhalon Biopharma press release.
